Genprex to Participate in a Monthly CEO Roadshow Webinar Series
July 20 2021 - 8:30AM
Business Wire
Series to highlight Genprex’s novel gene
therapy pipeline in cancer and diabetes
Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a
clinical-stage gene therapy company focused on developing
life-changing therapies for patients with cancer and diabetes,
today announced that its President and Chief Executive Officer,
Rodney Varner, will be participating in a webinar series with CEO
Roadshow to provide a company overview to investors on a monthly
basis from July through September 2021.
Details for the monthly CEO Roadshow webinar series:
Host: CEO Roadshow
Dates and Times:
- Wednesday, July 21 at 12 p.m. EDT
- Wednesday, August 18 at 11 a.m. EDT
- Wednesday, September 22 at 11 a.m. EDT
Webinar Link: https://bit.ly/3eoHeie
Mr. Varner will be available for questions following each
company presentation. The webinars will be recorded and available
for replay on Genprex’s website for a period of time. Replays will
also be available on CEORoadshow.com following each webinar.
The CEO Roadshow webinar series features small and mid-cap
stocks that are on the verge of a breakout or have other near-term
developments making them an attractive long-term investment
opportunity.
About Genprex, Inc.
Genprex, Inc. is a clinical-stage gene therapy company focused
on developing life-changing therapies for patients with cancer and
diabetes. Genprex’s technologies are designed to administer
disease-fighting genes to provide new therapies for large patient
populations with cancer and diabetes who currently have limited
treatment options. Genprex works with world-class institutions and
collaborators to develop drug candidates to further its pipeline of
gene therapies in order to provide novel treatment approaches.
Genprex’s oncology program utilizes its unique, proprietary,
non-viral ONCOPREX® Nanoparticle Delivery System, which the Company
believes is the first systemic gene therapy delivery platform used
for cancer in humans. ONCOPREX encapsulates the gene-expressing
plasmids using lipid nanoparticles. The resultant product is then
administered intravenously, where it is then taken up by tumor
cells that express proteins that are deficient. The Company’s lead
product candidate, REQORSA™ (quaratusugene ozeplasmid), is being
evaluated as a treatment for non-small cell lung cancer (NSCLC).
REQORSA has a multimodal mechanism of action that has been shown to
interrupt cell signaling pathways that cause replication and
proliferation of cancer cells; re-establish pathways for apoptosis,
or programmed cell death, in cancer cells; and modulate the immune
response against cancer cells. REQORSA has also been shown to block
mechanisms that create drug resistance. In January 2020, the U.S.
Food and Drug Administration granted Fast Track Designation for
REQORSA for NSCLC in combination therapy with AstraZeneca’s
Tagrisso® (osimertinib) for patients with EFGR mutations whose
tumors progressed after treatment with Tagrisso.
For more information, please visit the Company’s web site at
www.genprex.com or follow Genprex on Twitter, Facebook and
LinkedIn.
Cautionary Language Concerning Forward-Looking
Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. These forward-looking statements are made on the basis of
the current beliefs, expectations and assumptions of management,
are not guarantees of performance and are subject to significant
risks and uncertainty. These forward-looking statements should,
therefore, be considered in light of various important factors,
including those set forth in Genprex’s reports that it files from
time to time with the Securities and Exchange Commission and which
you should review, including those statements under “Item 1A – Risk
Factors” in Genprex’s Annual Report on Form 10-K.
Because forward-looking statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Such
statements include, but are not limited to, statements regarding:
the timing and success of Genprex’s clinical trials and regulatory
approvals; the effect of Genprex’s product candidates, alone and in
combination with other therapies, on cancer and diabetes; Genprex’s
future growth and financial status; Genprex’s commercial and
strategic partnerships including the scale up of the manufacture of
its product candidates; and Genprex’s intellectual property and
licenses.
These forward-looking statements should not be relied upon as
predictions of future events and Genprex cannot assure you that the
events or circumstances discussed or reflected in these statements
will be achieved or will occur. If such forward-looking statements
prove to be inaccurate, the inaccuracy may be material. You should
not regard these statements as a representation or warranty by
Genprex or any other person that Genprex will achieve its
objectives and plans in any specified timeframe, or at all. You are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of this press release.
Genprex disclaims any obligation to publicly update or release any
revisions to these forward-looking statements, whether as a result
of new information, future events or otherwise, after the date of
this press release or to reflect the occurrence of unanticipated
events, except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210720005275/en/
Genprex, Inc. (877) 774-GNPX (4679)
Investor Relations GNPX Investor Relations (877) 774-GNPX
(4679) ext. #2 investors@genprex.com
Media Contact Genprex Media Relations Kalyn Dabbs (877)
774-GNPX (4679) ext. #3 media@genprex.com
Genprex (NASDAQ:GNPX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Genprex (NASDAQ:GNPX)
Historical Stock Chart
From Apr 2023 to Apr 2024